{
    "clinical_study": {
        "@rank": "43587", 
        "arm_group": [
            {
                "arm_group_label": "water", 
                "arm_group_type": "Placebo Comparator", 
                "description": "just water"
            }, 
            {
                "arm_group_label": "L-CARNITINE AND MAGNESIUM (\"slim water\" product)", 
                "arm_group_type": "Experimental", 
                "description": "The experimental arm will receive a product \"slim water\", which contains 150 mg magnesium lactate and  2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the dual therapy of the     amino acid\n      L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with\n      non alcoholic fatty liver disease (NAFLD)."
        }, 
        "brief_title": "The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Alcoholic Fatty Liver Disease", 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to determine whether the dual therapy of the     amino acid\n      L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with\n      non alcoholic fatty liver disease.\n\n      the study is an interventional one in which 60 patients who by definition have non alcoholic\n      fatty licer disease (NAFLD) are divided randomly (double blind) into 2 groups: group 1:\n      \"study group\". receive a product (flavoured water) which contains L-CARNITINE an magnesium.\n      group 2: control. receive placebo. regular water. Length of trial - 12 weeks. The patients\n      will be followed on a weekly base and variuos parameters will be compared (weight, lipid\n      profile, insulin resistance etc.).\n\n      \"fibrotest\" will be used at the beginning of the trial and at the end (week 12) comparing\n      the fat content before and after the treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        age>18, <80 y evidence to non alcoholic fatty liver disease\n\n        Exclusion Criteria:\n\n        age<18, >80 y pregnancy renal failure congestive heart failure active malignancy liver\n        disease - etiology other than non alcoholic fatty liver disease (NAFLD).\n        hypothyroidism/cushing total prenteral nutrition (TPN) in the last 6 month"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956825", 
            "org_study_id": "MMC13023-13CTIL"
        }, 
        "intervention": {
            "arm_group_label": "L-CARNITINE AND MAGNESIUM (\"slim water\" product)", 
            "intervention_name": "\"slim water\"", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Carnitine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "non alcoholic fatty liver disease", 
            "LCARNITINE amino acid", 
            "magnesium", 
            "fat content"
        ], 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "contact": {
                "email": "danifel100@gmail.com", 
                "last_name": "DAN FELDMAN, MD", 
                "phone": "0522794025"
            }, 
            "contact_backup": {
                "email": "yonaki@clalit.org.il", 
                "last_name": "YONA KITAY, MD", 
                "phone": "09-7471560"
            }, 
            "facility": {
                "address": {
                    "city": "Kfar Saba", 
                    "country": "Israel"
                }, 
                "name": "Meir Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease", 
        "overall_contact": {
            "email": "danifel100@gmail.com", 
            "last_name": "DAN FELDMAN, MD", 
            "phone": "0522794025"
        }, 
        "overall_contact_backup": {
            "email": "yonaki@clalit.org.il", 
            "last_name": "YONA KITAY, MD", 
            "phone": "09-7471560"
        }, 
        "overall_official": {
            "affiliation": "Meir Medical Center", 
            "last_name": "DAN FELDMAN, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Clalit Health Services", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "effect of LCARNITINE and magnesium treatment on the liver fat content", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956825"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "hepatic enzyme profile, lipid profile, weight, inflammatory markers, insulin resistance", 
            "measure": "effect of L-CARNITINE and magnesium treatment on the metabolic panel", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "source": "Meir Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meir Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}